240 related articles for article (PubMed ID: 20842460)
1. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.
Motoi F; Rikiyama T; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2011 Feb; 18(2):371-9. PubMed ID: 20842460
[TBL] [Abstract][Full Text] [Related]
2. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
[TBL] [Abstract][Full Text] [Related]
3. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
4. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
[TBL] [Abstract][Full Text] [Related]
5. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Shukla PJ
Ann Surg; 2011 Aug; 254(2):385-6; author reply 386. PubMed ID: 21677560
[No Abstract] [Full Text] [Related]
6. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma].
Xie YB; Zhao P; Wang CF; Shan Y; Zhao DB; Liu Q; Bai XF
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):686-9. PubMed ID: 19173911
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
9. Invasive IPMN and MCN: same organ, different outcomes?
Kargozaran H; Vu V; Ray P; Bagaria S; Steen S; Ye X; Gagandeep S
Ann Surg Oncol; 2011 Feb; 18(2):345-51. PubMed ID: 20809175
[TBL] [Abstract][Full Text] [Related]
10. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N
Ann Surg Oncol; 2007 Nov; 14(11):3174-80. PubMed ID: 17694416
[TBL] [Abstract][Full Text] [Related]
11. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
12. [Surgical treatment of pancreatic carcinoma. Our experience].
Testi W; Coratti A; Tani F; Lorenzi M; Poggialini M; Genovese A; Spagnulo M; Terreni C; Picchianti D; Stefanoni M; Mancini S
Minerva Chir; 2000; 55(7-8):505-12. PubMed ID: 11140104
[TBL] [Abstract][Full Text] [Related]
13. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas.
Shimada K; Nara S; Esaki M; Sakamoto Y; Kosuge T; Hiraoka N
Pancreas; 2011 Apr; 40(3):464-8. PubMed ID: 21289526
[TBL] [Abstract][Full Text] [Related]
14. The natural history of resected pancreatic cancer without adjuvant chemotherapy.
Hernandez JM; Morton CA; Al-Saadi S; Villadolid D; Cooper J; Bowers C; Rosemurgy AS
Am Surg; 2010 May; 76(5):480-5. PubMed ID: 20506876
[TBL] [Abstract][Full Text] [Related]
15. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
16. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.
Strobel O; Hartwig W; Hackert T; Hinz U; Berens V; Grenacher L; Bergmann F; Debus J; Jäger D; Büchler M; Werner J
Ann Surg Oncol; 2013 Mar; 20(3):964-72. PubMed ID: 23233235
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
[TBL] [Abstract][Full Text] [Related]
18. [Factors influencing survival of patients with cancer of the pancreatic head after resection].
Gao CT; Li HK; Li Q
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):554-7. PubMed ID: 19950708
[TBL] [Abstract][Full Text] [Related]
19. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma.
Shimada K; Sakamoto Y; Sano T; Kosuge T
J Am Coll Surg; 2006 Sep; 203(3):345-52. PubMed ID: 16931307
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of re-resected cases of intraductal papillary mucinous neoplasms (IPMNs).
Yokoyama Y; Nagino M; Oda K; Nishio H; Ebata T; Abe T; Igami T; Nimura Y
Surgery; 2007 Aug; 142(2):136-42. PubMed ID: 17689677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
